ENDRA Life Sciences (NDRA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on August 6, 2024, with voting and participation available online or by phone.
Stockholders of record as of June 12, 2024, are eligible to vote on six key proposals, including director elections and major corporate actions.
The Board recommends voting in favor of all proposals, including amendments to the Certificate of Incorporation and ratification of the auditor.
Voting matters and shareholder proposals
Proposals include electing five directors, an advisory vote on executive compensation, authorizing issuance of shares for warrant exercises, increasing authorized shares, approving a reverse stock split, and ratifying the auditor.
The Board recommends voting FOR all proposals.
Shareholders can submit proposals for the 2025 meeting by February 20, 2025, and must comply with SEC rules.
Board of directors and corporate governance
The Board consists of five members, four of whom are independent under Nasdaq standards.
Committees include Audit, Compensation, and Corporate Governance and Nominating, all composed of independent directors.
The Chairman and CEO roles are combined, with flexibility to separate if needed.
Directors are encouraged to attend annual meetings, and a Code of Ethics applies to all directors and employees.
Latest events from ENDRA Life Sciences
- Q2 2026 net income turned positive, merger pending, and liquidity hinges on deal closure.NDRA
Q2 2026 - Net loss widened to $1.3M in Q1 2026, with no revenue and ongoing liquidity and Nasdaq compliance risks.NDRA
Q1 2026 - Operating expenses and net loss improved as clinical progress positions TAEUS Liver for future growth.NDRA
Q4 2025 - Pursuing a dual strategy of medical imaging innovation and major cryptocurrency investment.NDRA
Registration Filing - Key votes include director elections, share authorization, reverse split, and auditor ratification.NDRA
Proxy Filing - Shareholders will vote on director elections, compensation, auditor, share increase, and governance changes.NDRA
Proxy Filing - Facing Nasdaq delisting, a reverse stock split will be proposed to regain compliance.NDRA
Proxy Filing - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing and increase share price.NDRA
Proxy Filing - Q2 saw a $7.3M raise, 26% expense cut, narrowed loss, and leadership changes amid ongoing risks.NDRA
Q2 2024